Lugovskoy Alexey A, Reichert Janice M, Beck Alain
Merrimack Pharmaceuticals Inc.; Cambridge, MA USA.
Landes Bioscience; Austin, TX USA.
MAbs. 2012 Mar-Apr;4(2):134-52. doi: 10.4161/mabs.4.2.19426. Epub 2012 Mar 1.
The 7th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The 2011 version of the EAC was attended by nearly 250 delegates who learned of the latest advances and trends in the global development of antibody-based therapeutics. The first day focused on advances in understanding structure-function relationships, choosing the best format, glycoengineering biobetter antibodies, improving the efficacy and drugability of mAbs and epitope mapping. On the second day, the discovery of novel targets for mAb therapy, clinical pipeline updates, use of antibody combinations to address resistance, generation and identification of mAbs against new targets and biosimilar mAb development were discussed. Antibody-drug conjugates, domain antibodies and new scaffolds and bispecific antibodies were the topics of the third day. In total, nearly 50 speakers provided updates of programs related to antibody research and development on-going in the academic, government and commercial sectors.
由特拉平有限公司组织的第七届欧洲抗体大会（EAC），延续第四届EAC确立的传统，再次在瑞士日内瓦举行。2011年版的EAC有近250名代表出席，他们了解了基于抗体的治疗药物全球研发的最新进展和趋势。第一天聚焦于理解结构-功能关系方面的进展、选择最佳形式、糖基工程化生物优化抗体、提高单克隆抗体的疗效和可药用性以及表位作图。第二天讨论了单克隆抗体治疗新靶点的发现、临床研发进展更新、使用抗体组合应对耐药性、针对新靶点的单克隆抗体的产生和鉴定以及生物类似单克隆抗体的开发。抗体药物偶联物、结构域抗体、新的支架和双特异性抗体是第三天的主题。总共有近50位演讲者介绍了学术、政府和商业领域正在进行的抗体研发相关项目的最新情况。
